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Diabetes Mellitus type 1 is a disease caused by an autoimmune 
destruction of the insulin-producing ß-cells of the islets of 
Langerhans in the pancreas resulting in absolute insulin deficiency.  
Disease causes a chronically raised blood glucose concentration, 
which can be causes subsequent complications. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Although the causes of type 1 diabetes are not fully understood, several environmental factors such as viral 
infection may induce the β-cell–destructive immune response in genetically susceptible hosts. 
Islet-resident APC (DC or macrophages) shifts its phenotype into activators of an inflammatory response, and 
they migrate from islet environment toward peripheral lymphoid organs. 
Once there, APC eventually encounter the autoreactive T cells. 
 
. 
 
Glucose is carried across the cell membrane into cells by family of specialized transporter proteins 
called glucose transporters(GLUTs). 
GLUT-4 is responsible for insulin-stimulated glucose uptake in muscle an adipose tissue, and thus the 
classic hypoglycaemic action of insulin. 
 
Genetic susceptibility to type 1 diabetes is most closely 
associated with HLA genes. Clas II HLAs (HLA-D) play a 
role in presenting foreign and self-antigens to T-helpers 
lymphocytes and therefore in initiating the autoimmune 
process. [3] 
Type 1 Diabetis Mellitus     
 
(AAVs) are small 4.7 kb near single-stranded (ss) DNA 
Dependoviruses that belong to the Parvoviridae family. [1] 
 
Advantages of use AAV as a vector :  
  
 Lack of any associated human disease. 
 Broad host range. 
 Ability to infect growth-arrested cells. 
 Ability to carry non viral regulatory sequences 
without interference from the viral genome.  
No superinfection immunity associated.  
 
The efficiency of AAV infection has been improved through the 
use of certain serotypes of AAV that have different tropisms in 
vivo. 
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Figure 3. Production of AAV vectors. The two ITRs are the only AAV sequences preserved in the vectors, while 
transcriptional cassette ( promoter + gene + polyadenylation site) substitutes the rest of the genome. [1] 
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What is gene therapy?  
 
Gene therapy is a technique for correcting defective genes responsible for disease development. The most common approach for correcting faulty genes is to insert a “normal” gene into the genome to 
replace an “abnormal” disease-causing gene. 
 
OBJECTIVES : The aim of this work is know the general appropriate modifications of viral vector to lead correctly the genetic material to interest tissue and describe the AAV virus to understand how it 
has been used in experiments to cure Diabetes mellitus type 1. 
 
Patients with an advanced stage of Diabetes type 1 cannot be restore normal insulin level production by preventive gene therapy, due to the high 
destruction of β-cell.  Recovery from type 1 diabetes requires β -cell generation. 
 One approach to do so is by genetically engineering the endocrine pancreas in vivo to express factors that induce ß-cell replication and neogenesis and 
counteract the immune response. 
 
 Insulin and Glucokinase gene transfer to skeletal muscle corrects diabetes in dogs      
RESULTS 
PREVENTIVE 
ADJUNTIVE 
CURATIVE 
Preventive gene therapy is based on exploit immunoregulatory networks to promote hyporesponsiveness of autoaggressive immune cells as a viable 
means of improving or restoring normoglycemia. 
 
Adjuntive gene therapies are based on reducing immune reactions or inducing immune tolerance in transplantation. 
. 
 
 
This approach, demonstrates that it is possible to generate a “glucose sensor” in skeletal muscle through coexpression of 
glucokinase and insulin. The genes were one-time intramuscular administration in diabetic dogs through adeno-associated viral 
vectors of serotype 1. 
 
Five diabetic dogs were treated with one of the following: 
 
A. Insulin, administered twice daily. (Fig .6) 
B. Intramuscular injection of the glucokinase gene alone (AAV1-Gck). (Fig.7) 
C. Intramuscular injection of the insulin gene alone (AAV1-Ins) (Fig.8) 
D. Intramuscular injection of both the insulin and glucokinase genes(AAV1-Ins/GcK).(Fig 9) 
.  
 
Figure 8. Expression of glucokinase alone 
caused hyperglycemia in overload glucose 
conditions. [2] 
 
Figure 6. The dogs on twice daily insulin were 
better controlled but remained hyperglycemic. [2] 
 
Figure 7. Expression of insulin alone. The ability 
of dispose glucose was only moderately 
improved. [2] 
 
 
Figure 9. Expression of glucokinase and insulin. 
dogs quickly regained normoglicemia. [2] 
 
The liver enzyme glucokinase, compared to muscle glucokinase II in the skeletal 
muscle is not inhibited by glucose-6-phosphate, and shows kinetic cooperation 
with glucose. When expressed in skeletal muscle of transgenic mice, glucokinase 
remains active in the cytosol and facilitates glucose uptake only when blood 
glucose is high. However, during diabetes, constant basal levels of insulin are 
required to ensure the presence of GLUT4 on the cell membrane. 
 
Therefore, the regulation of glycemia was achieved by coexpression in skeletal 
muscle of glucokinase and low levels of insulin. [2] 
 
 
Figure 5. The mechanism of glucose-stimulated 
insulin secretion from the β-cell. [3] 
 
Gene therapy treatments for type 1 diabetes 
Figure 4. Gene and cell therapy strategies for type 1 diabetes. A number of strategies can 
be employed alone or in combination. Extracted from Gene- and cell-based therapeutics for 
type I diabetes mellitus. Gene therapy,2003;10. 
Figure 2. Antigen associated with class II HLA is 
presented to T cell. [3] 
Figure 1. Insulinitis. Chronic inflammatory 
cell infiltrate [3] 
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CONCLUSIONS : In reference to the cure of type 1 diabetes, the authors demonstrate for the first time in a large animal model that this gene therapy approach has a beneficial therapeutic effect for up to 4 years. 
This is a major advance in the field of gene therapy for DM. rAAV-based gene transfer vectors represent one of the most promising gene therapy systems and gain increasing popularity. 
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